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prostatectomy. Patients with perineural invasion who meet criteria for active surveillance should not be 
excluded from this treatment option.
Editorial Comment
 Perineural invasion (PNI) on needle prostatic biopsies as a marker of extraprostatic extension has 
been controversial. In almost all studies perineural invasion has been related to extraprostatic extension in 
univariate analysis but in only a few studies in multivariate analysis. The practical importance relates to the 
decision of whether to sacrifice part or all of the neurovascular bundle on the side of the biopsy with PNI in 
planning nerve-sparing radical prostatectomy. The study from Johns Hopkins has shown that cases that meet 
biopsy criteria for active surveillance yet have perineural invasion showed no significant difference from those 
without perineural invasion in terms of adverse findings at radical prostatectomy. Patients with perineural in-
vasion who meet criteria for active surveillance should not be excluded from this treatment option. Cases with 
biopsy criteria for active surveillance are considered insignificant having Gleason score 6 or less, 2 or fewer 
positive cores and 50% or less involvement in any positive core.
 The findings are very similar to a study from my Institution published in Int Braz J Urol (1). We found 
that tumor extent on needle biopsies influences the predictive value of PNI for pathologic stage > pT2 (pT3a 
and/or pT3b) on radical prostatectomies. In patients with more extensive tumors on needle biopsy, PNI pre-
dicted pathologic stage > pT2 on radical prostatectomy on univariate analysis but on multivariate analysis did 
not show independent predictive value. This finding is in accordance to most of the studies in the literature. 
In patients with less extensive tumors on biopsy (< 13.6% of tissue in mm containing carcinoma) and PNI, 
there was no association to any one clinical or pathological variables studied; no difference in the time to 
biochemical (PSA) progression-free outcome comparing to patients without PNI; and, no predictive value for 
pathological stage > pT2 on both univariate and multivariate analysis. With a higher number of small tumors 
currently detected, our results favor that PNI on needle biopsy should not be considered in the decision to 
sacrifice or not the neurovascular bundle in planning nerve-sparing radical prostatectomy.
Reference
1. Billis A, de Quintal MM, Meirelles L, Freitas LL, Magna LA, Ferreira U: Does tumor extent on needle 
prostatic biopsies influence the value of perineural invasion to predict pathologic stage > T2 in radical 
prostatectomies? Int Braz J Urol. 2010; 36: 439-47; discussion 448, 448-9.
Dr. Athanase Billis
Full-Professor of Pathology
State University of Campinas, Unicamp
Campinas, São Paulo, Brazil
E-mail: athanase@fcm.unicamp.br
Handling and reporting of transurethral resection specimens of the bladder in Europe: a web-based 
survey by the European Network of Uropathology (ENUP)
Lopez-Beltran A, Algaba F, Berney DM, Boccon-Gibod L, Camparo P, Griffiths D, Mikuz G, Montironi R, 
Varma M, Egevad L
Unit of Anatomic Pathology, Cordoba University Medical School, Cordoba, Spain
Histopathology. 2011; 58: 579-85. doi: 10.1111/j.1365-2559.2011.03784.x.
Urological Survey
546
Aims: To collect of information about European practices on handling and reporting of transurethral resection 
specimens of the bladder.
Methods and Results: The European Network of Uropathology is a communication network that includes 335 
pathology laboratories in 15 western European countries. A web-based questionnaire was answered by 52.2% 
of members. Some routines were adopted by a majority: formalin fixation (92.5%), separate containers for 
tumors and resection base (72%) and embedding of the entire specimen (60%). Cancer along/in adipose tis-
sue would be reported as pT3a by 19.5% and non-invasive urothelial carcinoma in prostatic ducts/glands as 
pT4a by 16.1%. Papillary urothelial neoplasia of low malignant potential is recognized by 72.6% but rarely 
reported. Immunohistochemistry is rarely or sometimes used for diagnosing bladder cancer by 91.7%, and the 
most frequently used markers are CK20 (76.9%), CK7 (66.7%) and Ki67 (38.8%). Only 24.8% report prog-
nostic markers, with Ki67 (84.4%) and p53 (64.4%) being most common. Only 50.9% use the International 
Society of Urological Pathology 1998/World Health Organization (WHO) 2004 grading system, followed by 
WHO 1973 (43.4%) and WHO 1999 (31.4%).
Conclusions: There is still variability in routine practice and a need for standardization of methodologies. 
These results may be helpful when judging what recommendations are reasonable to issue.
Editorial Comment
 Surveys on handling and reporting of surgical specimens are very important tools for consensus con-
ferences among pathologists. Due to the high frequency of transurethral resection specimens of the bladder, 
standardization of methodologies are of utmost importance.
 In TUR resections of malignant neoplasias, the pathology report should inform:
1. The histologic diagnosis. Most of the tumors are urothelial carcinomas. Sarcomas are very 
rare. There are several histologic variants of urothelial carcinomas.
2. Configuration. Papillary, non papillary, inverted growth.
3. Differentiation. Squamous differentiation is more frequent than glandular differentiation. 
There are other rare types of differentiation. Tumors with differentiation, in general, show a higher 
stage at diagnosis.
4.  Grading. Several systems may be used: grades 1, 2, and 3 (WHO); low-grade (corresponding 
to grade 1) and high-grade (corresponding to grades 2 and 3) (WHO/International Society of Urologi-
cal Pathology); and combined numbers, e.g. 1+2 (low-grade in most areas + high-grade as a second-
ary grade, 1+1 (low-grade in all areas examined), etc.
5.  Staging. According to the TNM: Tis (flat carcinoma in situ), Ta (papillary non invasive or 
papillary in situ), T1 (subepithelial connective tissue invasion), T2 (muscularis propria invasion). An 
important distinction for the pathologist is muscularis propria vs. muscularis mucosae. Invasion of the 
latter is still T1.
6. A very important information that should be included in the report is presence or not of sec-
tions of muscularis propria in the TUR. In cases of T1 without sections of muscularis propria, stage 
T2 cannot be excluded. A new TUR should be performed for an adequate staging.
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